Personalized Cancer Vaccines: $200k Questions and Calls to Watch Merck's 'Encouraging' Data
Discussion centers on personalized mRNA cancer vaccines, specifically noting progress involving Moderna and Merck's five-year follow-up data on melanoma. The technology is understood to be highly personalized, not a preventative standard vaccine.
The room is deeply divided. Some users, like 'SaveTheTuaHawk,' warn that science news from press releases is designed to boost stock prices, citing general mistrust in FDA hype. Others are cautiously optimistic, as 'bluGill' noted even a Phase 2 trial is cause for hope. The financial hurdle is massive; 'CompactFlax' pointed out costs reaching $200k for a customized procedure. Meanwhile, 'curbstickle' attacked insurance companies, claiming they profit by denying payment.
The consensus screams caution mixed with shock at the price tag. The core fault line pits the potential efficacy against the near-certainty of prohibitive cost, exacerbated by the fact that this therapy is not general coverage but a highly bespoke, expensive intervention.
Key Points
The extreme, individualized cost structure of personalized cancer vaccines.
The high cost is inescapable; 'CompactFlax' cited figures like $200k, and 'COASTER1921' underscored the 'INSANE' cost reality because they are not preventative.
Skepticism regarding the source and exaggeration of scientific trial data.
'SaveTheTuaHawk' explicitly advised caution, stating users should 'be wary of science by press releases' due to hype cycles.
Insurance companies' role in pricing out care.
'curbstickle' directly accused insurers of profiting by refusing payment rather than by covering treatment costs.
Positive framing of long-term trial milestones.
'Zirconium' relayed Merck's SVP quoting the five-year follow-up data as a 'meaningful milestone' and 'encouraging,' representing the pro-tech view.
The limitation of current procedures.
'dingus' separated visible excision from total cancer removal, noting the latter is not guaranteed by the standard reports.
Source Discussions (4)
This report was synthesized from the following Lemmy discussions, ranked by community score.